Ideas & Impact › Resources › Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure

Virologic failure (VF) is highly prevalent in sub-Saharan African children on antiretroviral therapy (ART) and is often associated with human immunodeficiency virus drug resistance (DR). Most children still lack access to routine viral load (VL) monitoring for early identification of treatment failure, with implications for the efficacy of second-line ART.

Explore Related Resources

Search More Resources

Journal Articles

HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique

Published January 2025

Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months […]

Topics:

HIV

Countries:

Mozambique

Program Tools

Breakthrough Champion Advocacy Toolkit

Published December 2024

This Breakthrough Champion Advocacy Toolkit is targeted towards strengthening the capacity of adolescents and youth to advocate for addressing HIV treatment inequalities to end AIDS. The Toolkit serves as a training manual for the Breakthrough Partnership’s adolescent champions to develop advocacy skills and gain knowledge about HIV treatment gaps and differentiated service delivery — which […]

Topics:

Adolescents

Countries:

Mozambique,

Nigeria,

Uganda

Journal Articles

Follow-Up Outcomes of Children, Adolescents, and Young People on Darunavir-Based Third-Line Antiretroviral Therapy

Published October 2024

Background: We assessed clinical outcomes among children, adolescents, and people younger than 25 years on darunavir-based antiretroviral therapy (ART) in 9 sub-Saharan African countries. Setting: Third-line ART centers in Cameroon, Eswatini, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe. Methods: From January 2019 to December 2022, we collected data from a cohort of children, adolescents, and young people […]

Topics:

Adolescents,

Pediatric HIV

Countries:

Cameroon,

Eswatini,

Kenya,

Lesotho,

Nigeria,

Rwanda,

Uganda,

Zambia,

Zimbabwe